Quick Answer
Vistagen Therapeutics, Inc. reported Diluted EPS of $1.67 per share (loss) for fiscal year 2025.
Vistagen Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.67 | -9.9% |
| 2024 | -$1.52 | +82.1% |
| 2023 | -$8.51 | +70.7% |
| 2016 | -$29.08 | -174.1% |
| 2015 | -$10.61 | -178.5% |
| 2014 | -$3.81 | -200.0% |
| 2013 | -$1.27 | -53.0% |
| 2012 | -$0.83 | +54.1% |
| 2011 | -$1.81 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.45 | +2.2% | +16.7% |
| September 30, 2025 | -$0.54 | -28.6% | -14.9% |
| June 30, 2025 | -$0.47 | -34.3% | -2.2% |
| December 31, 2024 | -$0.46 | -109.1% | -9.5% |
| September 30, 2024 | -$0.42 | +36.4% | -20.0% |
| June 30, 2024 | -$0.35 | +62.8% | -59.1% |
| December 31, 2023 | -$0.22 | — | +66.7% |
| September 30, 2023 | -$0.66 | — | +29.8% |
- Vistagen Therapeutics, Inc. showed a decrease of -9.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2011–2025 period, Vistagen Therapeutics, Inc.’s diluted eps has grown by 7.7% (from $1.81 per share (loss) to $1.67 per share (loss)).
- The most recent figure is from Vistagen Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: